Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Hodgkin Disease × Lenograstim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Hodgkin Disease 1 Castrate Resistant Prostate Cancer 1

Interventions

pembrolizumab 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 etoposide phosphate 1 camrelizumab 1 aldesleukin 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 Melphalan 1 Lenograstim 1 Interleukin-2 1 Interferon-gamma 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Etoposide 1 Decitabine 1 Cytarabine 1 Cyclosporins 1 Cyclosporine 1 Carmustine 1 Brentuximab Vedotin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01085058 2010-03-11

CU01

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡